ClinicalTrials.Veeva

Find clinical trials for Multiple Sclerosis (MS) in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Toronto, ON, CAN:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Drug: Siponimod
Drug: Ofatumumab

Phase 3

Novartis
Novartis

Toronto, Ontario, Canada and 72 other locations

This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

Toronto, Ontario, Canada and 161 other locations

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a durat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Other: Ocrelizumab Placebo
Other: Fingolimod Placebo

Phase 3

Roche
Roche

Toronto, Ontario, Canada and 118 other locations

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (ARTIOS)

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: Ofatumumab

Phase 3

Novartis
Novartis

Toronto, Ontario, Canada and 122 other locations

A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis

and female participants aged 18 to 60 years with relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple...

Active, not recruiting
Multiple Sclerosis
Drug: SAR443820
Other: Placebo

Phase 2

Sanofi
Sanofi

Toronto, Ontario, Canada and 40 other locations

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)

This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sc...

Active, not recruiting
Progressive Multiple Sclerosis (PMS)
Drug: Ocrelizumab

Phase 3

Roche
Roche

Toronto, Ontario, Canada and 125 other locations

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

relapse rate (ARR) in participants with relapsing forms of MSSecondary Objective:To assess efficacy of SAR442168 compared to teriflunomide (...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Placebo to match Tolebrutinib
Drug: Teriflunomide HMR1726

Phase 3

Sanofi
Sanofi

Toronto, Ontario, Canada and 178 other locations

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis

ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-p...

Active, not recruiting
Amyotrophic Lateral Sclerosis
ALS
Drug: Placebo
Drug: ABBV-CLS-7262

Phase 1

Calico Life Sciences

London, Ontario, Canada and 13 other locations

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

relapse rate (ARR) in participants with relapsing forms of MSSecondary Objective:To assess efficacy of SAR442168 compared to teriflunomide (...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Placebo to match Teriflunomide
Drug: Teriflunomide HMR1726

Phase 3

Sanofi
Sanofi

Hamilton, Ontario, Canada and 185 other locations

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (O'HAND)

This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple...

Enrolling
Multiple Sclerosis, Primary Progressive
Drug: Ocrelizumab
Drug: Placebo

Phase 3

Roche
Roche

Toronto, Ontario, Canada and 209 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems